Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Fuller

Adult Reconstructive Orthopaedic Surgery Carrollton, TX Medical Doctor

NPI 1396972386 CMS profile 108560

4780 N Josey Ln, Ste 240, Carrollton, TX 75010

Open in the dashboard

General payments

$218,477

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Fuller of Carrollton, TX is reported in the CMS Open Payments database as having received $218,477 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122,073 68
2024 General $67,603 65
2023 General $14,793 49
2022 General $1,826 24
2021 General $1,848 27
2020 General $677 11
2019 General $9,657 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Fuller
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Brian Fuller were reported at $122,073. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Brian Fuller Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $9,657 $1,416 $292–$9,336 $163
2020 $677 $647 $141–$6,474 $114
2021 $1,848 $1,073 $211–$6,497 $132
2022 $1,826 $1,217 $236–$6,299 $149
2023 $14,793 $1,082 $246–$6,818 $160
2024 $67,603 $1,575 $323–$8,944 $164
2025 $122,073 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $174,537 107 payments
  2. Kyocera Medical Technologies, Inc. $20,079 6 payments
  3. Smith+Nephew, Inc. $5,494 13 payments
  4. Zimmer Biomet Holdings, Inc. $5,068 27 payments
  5. Histosonics, Inc. $2,431 1 payment
  6. Brixton Biosciences, Inc. $2,129 2 payments
  7. Medacta USA, Inc. $2,016 21 payments
  8. Ortho Development Corporation $1,506 5 payments
  9. Uoc USA Inc $1,068 4 payments
  10. Pylant Medical $945 7 payments
  11. Other $3,204 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $174,826 55 payments
  2. Travel and Lodging $27,805 57 payments
  3. Food and Beverage $8,046 154 payments
  4. Honoraria $4,050 2 payments
  5. Education $3,750 1 payment
Products named General payments · program years 2019–2025
  1. DJO SURGICAL Joint Implants $25,577 26 payments
  2. DJO SURGICAL Joint Implants $19,883 11 payments
  3. DJO SURGICAL Joint Implants $18,852 26 payments
  4. DJO SURGICAL Joint Implants $10,688 1 payment
  5. DJO SURGICAL Joint Implants $7,161 8 payments
  6. DJO SURGICAL $4,972 5 payments
  7. DJO SURGICAL Joint Implants $3,202 4 payments
  8. Avenir $2,979 3 payments
  9. DJO SURGICAL Joint Implants $2,649 2 payments
  10. Neural Ice $2,129 2 payments
  11. Other $20,723 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

2,739

Median for Orthopedic Surgery: 203

Drug cost

$29,151

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tranexamic Acid Generic 183 $7,324
Celecoxib Generic 231 $6,860
Diclofenac Sodium Generic 485 $5,451
Gabapentin Generic 273 $1,918
Ondansetron Odt Ondansetron Brand 179 $1,896
Meloxicam Generic 425 $1,174
Dexamethasone Generic 185 $1,043
Cefadroxil Generic 181 $1,020
Tramadol Hcl Generic 233 $869
Oxycodone Hcl Generic 192 $779

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$308,694

Of which drugs: $46,439

Medicare patients

590

Average age 75

Services billed

4,599

372 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 29%
Diabetes 27%
Chronic kidney disease 24%
Depression 20%
Osteoporosis 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 32 56 $30,544
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 19 31 $12,383
Injection, ketorolac tromethamine, per 15 mg J1885 Office 132 326 $166
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 80 910 $77

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APONVIE
  • Heron Therapeutics, Inc. $31
$31 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $8
$8 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record